1. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension;Galiè;Eur. Heart J.,2016
2. Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat;Rahaghi;Pulm. Circ.,2022
3. Sex and gender in pulmonary arterial hypertension;Cheron;Eur. Respir. Rev.,2021
4. European Medicines Agency. European public assessment report (EPAR): Adempas (riociguat). Product information (first published 2014, last updated 2022). 〈https://www.ema.europa.eu/en/medicines/human/EPAR/adempas#product-information-section〉 [last accessed on 04 January 2023].
5. European Medicines Agency. EPAR: Opsumit (macitentan). Product information (first published 2014, last updated 2022). 〈https://www.ema.europa.eu/en/medicines/human/EPAR/opsumit#product-information-section〉 [last accessed on 04 January 2023].